MEDICAL ONCOLOGY

CLOSED TO RECRUITMENT — AUSTRALIA

Abbrev. Title

AK117-101

Protocol Title

A Phase 1 Multicenter, Open Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination with AK104 in Subjects with Relapsed/Refractory Advanced or Metastatic Solid Tumours or Lymphomas

AK117-101

A Phase 1 Multicenter, Open Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination with AK104 in Subjects with Relapsed/Refractory Advanced or Metastatic Solid Tumours or Lymphomas

AK119-102 A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 in Combination with AK104 in Subjects with Advanced or Metastatic Solid Tumours

AK119-102 A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 in Combination with AK104 in Subjects with Advanced or Metastatic Solid Tumours

ANZ1701 AFT-38 PATINA A Randomized, Open Label, Phase 3 Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

ANZGOG1601 PHAEDRA A Phase II Trial of Durvalumab (MEDI4736) in Advanced Endometrial Cancer

ANZUP1303 ENZARAD Randomised Phase 3 Trial of Enzalutamide in Androgen Deprivation Therapy with Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

ANZUP1304 ENZAMET Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

ANZUP1601 KEYPAD A Phase 2 Trial of Pembrolizumab and Denosumab in Advanced Clear-Cell Renal Cell Carcinoma (CCRCC) Progressing After a VEGF-TKI

ANZUP1602 UNISoN Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma